360 High-Risk Vulnerability Immunization Tool V2.0 vs Armis Centrix™ for VIPR: 2026 Comparison

360 High-Risk Vulnerability Immunization Tool V2.0

Startups and SMBs with Windows-heavy infrastructure and patching backlogs should run 360 High-Risk Vulnerability Immunization Tool V2.0 first; it immunizes against the specific CVEs that drive ransomware campaigns (MS17-010, CVE-2019-0708) without requiring immediate OS updates. The tool supports Windows 7 through current versions and deploys on-premises, meaning air-gapped networks can actually use it. Skip this if you're looking for NIST PR.PS coverage beyond platform hardening,this tool stops known exploits, not supply chain attacks or firmware-level threats.

Armis Centrix™ for VIPR

Healthcare mid-market and enterprise teams that need vulnerability management tied directly to patient safety,not just IT risk,should run Armis Centrix for VIPR. Its Clinical Impact Score reorders remediation by actual clinical consequence rather than CVSS score alone, a distinction that matters when you have 10,000 medical devices and three remediation slots. The platform covers NIST ID.AM and ID.RA solidly, with real-time device inventory and threat intelligence, though it leans toward asset visibility over response automation; this is a prioritization engine first, not a ticketing replacement. Wrong tool if your infrastructure team wants device management divorced from clinical context or needs deep integration with your existing vulnerability scanner output.